



PATIENT INFORMATION

Patient Name: _____ DOB: _____ Phone: _____ Sex: M F Ht: _____ Wt: _____ lbs kg
 Primary Language: _____ Allergies: _____

<ICD 10 CODE REQUIRED> DIAGNOSIS & CLINICAL INFORMATION

ICD 10 Code (PROVIDE COMPLETE CODE)

- M05. _____ Rheumatoid Arthritis w/Rheumatoid Factor
- M06. _____ Rheumatoid Arthritis w/o Rheumatoid Factor
- M31.30 Granulomatosis w/Polyangiitis (Wegener's Granulomatosis GPA)
- M31.7 Microscopic Polyangiitis
- Other: _____

REQUIRED: Demographics & Most Recent: H&P, clinical notes, labs, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy

PRESCRIPTION

Pre-Medications

- Acetaminophen: 650 mg PO
- Cetirizine 10 mg PO
- Dexamethasone: _____ mg IV
- Diphenhydramine: 25 mg PO
- Diphenhydramine: 25 mg IV
- Other: _____
- Acetaminophen: _____ mg PO
- Famotidine: _____ mg IV
- Loratadine 10 mg PO
- Methylprednisolone: _____ mg IV
- Ondansetron 4 mg IV

Lab Orders

- CBC w/diff: every _____ weeks month
- CMP: every _____ weeks month
- Other: _____ weeks month

Drug

- Rituximab **OR** Biosimilar as dictated by patient's insurance*
**Oregon Specialty Infusion will determine appropriate product based upon benefit investigation*
- OR**
- Rituximab product _____ (DO NOT SUBSTITUTE)

Adverse Events: In the event of an adverse reaction occurring at Oregon Specialty Infusion clinic, OSI will utilize their adverse reactions protocol

Loading Dose (SELECT ONE)

- IV:** Infuse 500 mg at weeks 0 and 2
- IV:** infuse 1000 mg at weeks 0 and 2
- IV:** Infuse _____ mg at weeks 0 and 2

Maintenance Dose (SELECT ONE)

- IV:** Infuse _____ mg Single Dose every _____ weeks months x 1 year
- IV:** Infuse _____ mg initial dose at Day 1 followed by 2nd dose on Day 15, then repeat cycle every _____ months x 1 year
- IV:** Infuse _____ mg every week for 4 weeks total, then repeat cycle every _____ months x 1 year
- IV:** Other frequency _____ x 1 year

Is the patient on any other disease modifying therapy? Yes No

If yes, please note therapy and last dose: _____

PRESCRIBING INFORMATION

Prescriber Name: _____ Signature: _____
 Date: _____ NPI # _____ Specialty: _____
 Office phone #: _____ Office Fax #: _____